Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?

Alex Renner, Suraj Rajesh Samtani, Arnaldo Marín, Mauricio Burotto

Abstract


Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA), the first prospective phase III trial comparing a targeted agent alone (sunitinib) versus nephrectomy plus sunitinib, has been recently published, showing non-inferiority for the nephrectomy-sparing arm. In this article, we discuss the impact of nephrectomy including its immune-mediated effects, surgical morbidity and mortality, and the clinical data supporting the indications of nephrectomy in order to analyze the CARMENA trial in context, with the aim to identify optimal strategies for different patient populations in the metastatic setting.


Keywords


cytoreductive nephrectomy; immunotherapy; metastatic renal cell carcinoma; sunitinib; surgical outlook

Full Text:

HTML PDF XML


DOI: http://dx.doi.org/10.15586/jkcvhl.2019.114

Article Metrics

Metrics Loading ...




Copyright (c) 2019 Suraj Rajesh Samtani

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.